


## Raloxifene

|                           |   |       |          |
|---------------------------|---|-------|----------|
| <b>Cat. No.:</b>          | HY-13738  |       |          |
| <b>CAS No.:</b>           | 84449-90-1  |       |          |
| <b>Molecular Formula:</b> | C <sub>28</sub> H <sub>27</sub> NO <sub>4</sub> S |       |          |
| <b>Molecular Weight:</b>  | 473.58  |       |          |
| <b>Target:</b>            | Estrogen Receptor/ERR                             |       |          |
| <b>Pathway:</b>           | Vitamin D Related/Nuclear Receptor                |       |          |
| <b>Storage:</b>           | Powder  | -20°C | 3 years  |
|                           |   | 4°C   | 2 years  |
|                           | In solvent  | -80°C | 6 months |
|                           |   | -20°C | 1 month  |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (211.16 mM; Need ultrasonic)

| Concentration             | Solvent | Mass      |            |            |
|---------------------------|---------|-----------|------------|------------|
|                           |         | 1 mg      | 5 mg       | 10 mg      |
| Preparing Stock Solutions | 1 mM    | 2.1116 mL | 10.5579 mL | 21.1158 mL |
|                           | 5 mM    | 0.4223 mL | 2.1116 mL  | 4.2232 mL  |
|                           | 10 mM   | 0.2112 mL | 1.0558 mL  | 2.1116 mL  |

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

Estrogen receptor

#### In Vivo

Raloxifene (4 mg/kg; intragastrically; daily for 13 weeks) significantly prevents bone loss in ovariectomized (OVX) rats<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

|                 |  |
|-----------------|--|
| Animal Model:   | Female, 12-week-old, Wistar rats (OVX rats) <sup>[1]</sup> |
| Dosage:         | 4 mg/kg  |
| Administration: | Intragastrically; daily for 13 weeks                       |

---

Result:

Significantly increased the levels of E2 in OVX rats and significantly decreased the levels of BGP.

---

## CUSTOMER VALIDATION

- Free Radic Biol Med. 2017 Apr 10;108:404-417.
- Viruses. 2021 Jun 28;13(7):1255.
- ACS Omega. 2023 Jun 14.
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681.
- J Pharmaceut Biomed. 2020, 113870.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Khovidhunkit W, et al. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med. 1999;130(5):431-439.
- [2]. Xu H, et al. Effect of caffeine on ovariectomy-induced osteoporosis in rats. Biomed Pharmacother. 2019;112:108650.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA